• Overview
  • Eligibility
  • More info
  • Locations

Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia (NCT03027102)

Ozmosis Research Inc.
This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise ~1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.
  • Biological: DNT cells
    DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    All
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers

    1 locations

    Canada (1)
    • Princess Margaret Cancer Centre
      not yet recruiting
      Toronto, Ontario, Canada, M5G2M9
    Status:
    not yet recruiting
    Type:
    Interventional
    Phase:
    Start:
    28 February, 2017
    Updated:
    06 February, 2017
    Participants:
    24
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!